Friday, March 01, 2019 7:31:53 PM
Again, I'd like to remind everyone here that recently there was the capital raise performed at around $5.65/sh or so and IGC raised in excess of thirty million dollars.
This means that 30 million dollars worth of stock was purchased directly from the company at over $5 per share and proceeds used to fund operations.
It was that very offering that forced the shares to be sold down from $12 to the mid $5's which makes perfect sense seeing as how that's where the company did their offering.
Subsequent to that, the shares were delisted by the NYSE for reasons clearly stated by the NYSE.
Months passed and IGC languished, trading below $0.45 a share.
Once the NYSE vetted IGC's balance sheet, they allowed them to be re-listed on the NYSE.
So you will notice that now , many that got screwed over on the downdraft, due solely to the NYSE's decision to de-list , are now averaging down on their positions and that is why the share price is slowly stair stepping higher, especially having to contend with the sell pressure from those that had been purchasing sub $0.45 shares and came to market for profits.
Clearly volume indicates that the bottom has been in and institutional investors have taken over.
The warrants just appear to be the cheapest way to play this but I'm trading both the stock and the the warrants - simply trying to time short-term bottoms and short-term tops and profiting by Trading between them, versus simply buying and holding and dealing with all the stress and volatility in not realizing gains when presented
This means that 30 million dollars worth of stock was purchased directly from the company at over $5 per share and proceeds used to fund operations.
It was that very offering that forced the shares to be sold down from $12 to the mid $5's which makes perfect sense seeing as how that's where the company did their offering.
Subsequent to that, the shares were delisted by the NYSE for reasons clearly stated by the NYSE.
Months passed and IGC languished, trading below $0.45 a share.
Once the NYSE vetted IGC's balance sheet, they allowed them to be re-listed on the NYSE.
So you will notice that now , many that got screwed over on the downdraft, due solely to the NYSE's decision to de-list , are now averaging down on their positions and that is why the share price is slowly stair stepping higher, especially having to contend with the sell pressure from those that had been purchasing sub $0.45 shares and came to market for profits.
Clearly volume indicates that the bottom has been in and institutional investors have taken over.
The warrants just appear to be the cheapest way to play this but I'm trading both the stock and the the warrants - simply trying to time short-term bottoms and short-term tops and profiting by Trading between them, versus simply buying and holding and dealing with all the stress and volatility in not realizing gains when presented
Recent IGC News
- IGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau Conference • ACCESS Newswire • 05/15/2026 12:00:00 PM
- IGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phase • ACCESS Newswire • 04/28/2026 04:15:00 PM
- IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion • ACCESS Newswire • 04/22/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/20/2026 08:01:33 PM
- IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia • ACCESS Newswire • 04/20/2026 12:30:00 PM
- IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout • ACCESS Newswire • 04/14/2026 12:30:00 PM
- Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts • ACCESS Newswire • 04/08/2026 04:45:00 PM
- IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's Disease • ACCESS Newswire • 04/07/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/06/2026 08:02:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/06/2026 08:01:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/30/2026 09:43:01 PM
- IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness • ACCESS Newswire • 03/30/2026 12:00:00 PM
- IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025 • ACCESS Newswire • 03/19/2026 01:00:00 PM
- IGC Pharma to Showcase AI Platform with Alzheimer's Disease Data Initiative at ADPD 2026 • ACCESS Newswire • 03/18/2026 01:00:00 PM
- IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer's Research • ACCESS Newswire • 02/26/2026 01:30:00 PM
- IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets • ACCESS Newswire • 02/24/2026 01:30:00 PM
- IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial • ACCESS Newswire • 02/23/2026 01:30:00 PM
- IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances • ACCESS Newswire • 02/17/2026 01:30:00 PM
- IGC Pharma to Participate in Fireside Chat With Ascendiant Capital Markets • ACCESS Newswire • 02/12/2026 01:30:00 PM
- IGC Pharma Announces Equity Research Update by Alliance Global Partners • ACCESS Newswire • 02/10/2026 01:30:00 PM
- IGC Pharma Expands Phase 2 CALMA Trial into Colombia's Premier Alzheimer's Research Center • ACCESS Newswire • 02/09/2026 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 09:02:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/08/2025 05:15:14 AM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 12/03/2025 09:05:25 PM
